

EVOiR&D – Integrated Data-Driven Research & Development

- Industry leading approach to integrate critical path activities for the most efficient delivery of IND-enabled clinical candidates, in multiple disease areas and therapeutic modalities
- Fully integrated, modality-agnostic resources from ideation through to development incorporating critical components such as biomarker development, proprietary computational and AI/ML approaches, and development expert panels
- World-class scientific talent that is recruited, trained, retained and passionate about their focus on high quality research
- Creating and driving the science of drug discovery that enables the industry ambitions with innovation from idea to IND





Rapid progression to the clinic

Evotec is a leading drug discovery & development partnership company with an outstanding track record of delivering preclinical and clinical candidates. The combination of state-of-the-art capabilities, with a fully integrated interdisciplinary approach built on industry-leading drug discovery & development knowledge, maximizes the probability of successful drug discovery outcomes for our partners.



World-class drug discovery & development with consultant-level expertise

Evotec offers the following, across modalities:

> World-class integrated drug discovery with a disease-area specific, maximally efficient team model

- Enhanced drug discovery to development transition practices that maximise the opportunity for clinical success
- ▶ Fully integrated drug development operations managed by experts with consultant-level experience
- Unique clinical management approaches that enhance clinical study quality while minimizing timelines
- ▶ Late-stage support for API and Drug Product through Phase 3 and/or commercial supply*

*Commercial supply options are limited by scale and depend on the size of the target patient population PDC: Preclinical Development Candidate; IND: Investigational New Drug Application (used interchangeably with CTA as per ex-US regulatory approaches)

Trusted partner through >20 years of delivery: Track record and current capacity of ~4500 employees

Strong track record

- >500 assay developments and high-throughput screens
- >160 Hit-to-lead campaigns
- >350 patents with Evotec scientists as named inventors
- >120 preclinical candidates delivered
- ▶ ~45 INDs supported since 2016
- 48 INDiGO programs successfully completed
- Decades of new technology development (FCS++, iPSCs, FMO, advanced proteomics, novel disruption of cell signalling ...)

Globally leading current state and accelerating

- ► ~70 high-throughput screens per year, including BSL2+ & BSL3, phenotypic, biophysics
- >80 concurrent integrated drug discovery projects in 2020
- >15 preclinical INDiGO packages ongoing
- ➤ All-modalities design, including small molecules, biologics (antibodies & bifunctionals), cell therapy, gene therapy, antisense, RNA, exosomes, protein degradation

Some of the key factors that have enabled Evotec to deliver successful outcomes in multiple integrated projects in collaboration with and for our clients include:

- Experience in a broad range of target classes and all-modalities design, including small molecules, biologics (antibodies & bifunctionals), cell therapy, gene therapy, antisense, RNA, exosomes, protein degradation
- Breadth and depth of our extensive disease biology, drug discovery and development expertise to deliver PDC/IND candidates for difficult targets against challenging timelines
- Leading approaches to identify and expand hits, including MS-based, phenotypic, fragment-based, virtual and the application of machine learning and AI
- High quality hypothesis driven and computationally enabled molecular design, coupled with fit-for-purpose screening cascades drive rapid DMTA cycles, in order to achieve the Target Product Profile in the minimum number of iterations
- AI/ML is being used in combination with natural language processing and high-performance computing to identify potential biomarkers for clinical evaluation or as PoC tools in pre-clinical and early clinical studies
- The massive amount of data created by Evotec is being combined with public data to build knowledge graphs that enable a deeper understanding of disease and mechanisms – providing insight to drug targets as well as biomarkers

- Disease biology relevant and mechanism-driven assays and models applied in a rationale and efficient way such as translational biology strategies for the early identification of biomarkers using patient-derived iPSCs, cells and tissues combined with omics approaches
- Deep understanding of PK/PD relationship and human dose prediction as early as possible
- A fully dedicated scientific preclinical and clinical expert team to aid in the discovery and validation of Biomarkers supporting our R&D portfolio to improve (pre)clinical success and translation
- Access to state-of-the-art platforms and pertinent human samples (with associated clinical data) to support Precision Medicine efforts and enable translation from bench-to-bedside and back
- Focus on embedding development quality and de-risking during lead optimisation, to ensure smooth transition into development and reduced risk of downstream attrition and delay
- ► Fully transparent resourcing with complete flexibility depending on project progress
- Expert project strategy and leadership across all critical functions to drive forward achieving the desired outcomes
- Expert support in the design and execution of global clinical trials that fit seamlessly into Evotec's fully integrated research and development platform, significantly reducing the overall time to clinical development
- Regulatory Affairs support throughout the whole R&D program

Drug discovery and development always requires elements of problem-solving and innovation to achieve success. We believe connected and experienced individuals working in highly effective teams, maximize the chances of success and the speed with which the breakthroughs are conceived and realized. By working with Evotec, your project is in the safest hands and has the best chance of success for you and for the patients you are striving to help.